Imipenem E Cilastatina Hikma Farmacêutica (Cilastatin, Imipenem)

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, which prevents peptidoglycan cross‑linking and leads to bacterial lysis. Cilastatin, co‑formulated with imipenem, blocks renal dehydropeptidase I, an enzyme that would otherwise degrade imipenem, thereby preserving its antibacterial activity and increasing urinary concentrations.

The dosage of Imipenem E Cilastatina Hikma is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local antimicrobial guidelines. Only a qualified healthcare professional should set the appropriate dose and infusion schedule.

The safety of Imipenem E Cilastatina in pregnancy and lactation has not been definitively established. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order Imipenem E Cilastatina, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain handling if needed) and assists with import documentation.

Imipenem, combined with cilastatin, offers a broad spectrum of activity similar to other carbapenems such as meropenem or ertapenem, but its stability against renal dehydropeptidase I provides higher urinary concentrations. Choice among carbapenems depends on local resistance patterns, pharmacokinetic considerations, and patient‑specific factors such as renal function and potential drug interactions.

Imipenem E Cilastatina should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not store at room temperature for extended periods, as stability may be compromised.

The medication is supplied as a sterile powder for reconstitution and is administered by intravenous infusion. The reconstituted solution should be diluted according to the manufacturer’s instructions and infused over the recommended time period, typically 30 minutes, under aseptic conditions by qualified healthcare personnel.

The most serious risks include the potential for seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, and antibiotic‑associated colitis caused by Clostridioides difficile. Prompt recognition and management of these events are essential.

Patients with a known hypersensitivity to imipenem, cilastatin, or other β‑lactam antibiotics should not receive this product. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those taking medications that lower the seizure threshold, unless the benefits clearly outweigh the risks.